Why the study?
Does gemfibrozil reduce plasma prothrombin fragment F1+2 concentration in male patients with coronary heart disease?
Does gemfibrozil reduce plasma prothrombin fragment F1+2 concentration in male patients with coronary heart disease?
Gemfibrozil reduces procoagulant activity, as measured by plasma prothrombin fragment F1+2, in men with coronary heart disease.
No takes yet. Share an insight, caveat, or question.
Gemfibrozil may confer antithrombotic effects in men with coronary heart disease; extends evidence for non-lipid benefits of fibrates.
Wilkes et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: